Page 6 - Which Exceeded News Today : Breaking News, Live Updates & Top Stories | Vimarsana

5% Below are specific updates on pipeline assets since our previous earnings announcement on October 27, 2020: Abrocitinib (PF-04965842) In November 2020, Pfizer announced positive top-line results from the fifth Phase 3 trial of abrocitinib, JADE REGIMEN, a 52-week study which investigated abrocitinib in patients 12 and older with moderate to severe atopic dermatitis (AD) following response to initial open label induction treatment with abrocitinib 200 mg. Patients were randomized into one of three arms: 200 mg, 100 mg or placebo. Both doses of abrocitinib met the primary endpoint, resulting in significantly fewer patients experiencing a loss of response requiring rescue treatment compared to those randomized to placebo. Both doses also met the key secondary endpoint of a larger percentage of patients maintaining an Investigator’s Global Assessment (IGA) response of clear or almost clear relative to placebo.

South africaComunidad autonoma de catalunaSouth africanFrank damelioMylannv mylanValneva lymeVyndaqel vyndamaxAlbert bourlaEli lillyUpjohn incHealth incSangamo therapeutics incMerck co incMerck kgaPfizer incAbbvie inc